Get the content you want anytime you want.

IV to PO Conversions: What Should Clinicians Know?


Emily Heil, PharmD, BCPS-AQ ID, assistant professor at the University of Maryland School of Pharmacy, and Contagion® Editorial Advisory Board Member, discusses some points to be mindful of when considering IV to PO conversions.
Interview Transcript (slightly modified for readability
“IV [intravenous] to PO [oral] conversions are something we think of as sort of ‘low-hanging fruit’ in the world of antimicrobial stewardship because they’re relatively easy-to-do interventions that can have a major impact. Any time you’re able to change a patient from an IV to oral medication, there’s data that you can decrease the hospital length-of-stay, less chance of line-related infections if you’re able to remove that patient’s IV access if they no longer need it. Also, you usually get some bonus cost-savings, as oral medications tend to be less expensive than their IV counterparts.
So, that’s a very low-hanging fruit intervention in the world of stewardship in that it’s relatively simple but can have a big impact.
As long as you’re choosing the right drug for your IV to PO conversion, it shouldn’t affect efficacy. You want to focus on drugs that are 100% bio-available, meaning that their oral formulation will get serum levels that equate their IV counterparts.”
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.

Advocacy and Research Foundation Partners
Big advances in treatment can